NO304352B1 - Kontrastmedier - Google Patents

Kontrastmedier Download PDF

Info

Publication number: NO304352B1
Authority: NO; Norway
Prior art keywords: contrast; sodium; calcium; concentration; contrast media
Prior art date: 1990-03-09

Application number

NO923485A

Other languages

English (en)

Norwegian (no)

Other versions

NO923485L (no

NO923485D0 (no

Inventor

Torsten Almun

Lars Booth

Per Jynge

Audun Nesheim Iksendal

Original Assignee

Nycomed As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-09

Filing date

1992-09-08

Publication date

1998-12-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO304352(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-03-09 Priority claimed from EP90200580A external-priority patent/EP0390242B1/en

1992-09-08 Application filed by Nycomed As filed Critical Nycomed As

1992-09-08 Publication of NO923485D0 publication Critical patent/NO923485D0/no

1992-11-05 Publication of NO923485L publication Critical patent/NO923485L/no

1998-12-07 Publication of NO304352B1 publication Critical patent/NO304352B1/no

Links

239000002872 contrast media Substances 0.000 title claims abstract description 148
229940039231 contrast media Drugs 0.000 title description 57
239000011575 calcium Substances 0.000 claims abstract description 60
239000011734 sodium Substances 0.000 claims abstract description 54
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 32
229910052708 sodium Inorganic materials 0.000 claims abstract description 32
239000011777 magnesium Substances 0.000 claims abstract description 28
229960004359 iodixanol Drugs 0.000 claims abstract description 25
NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims abstract description 25
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims abstract description 17
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 16
229960001025 iohexol Drugs 0.000 claims abstract description 16
239000011591 potassium Substances 0.000 claims abstract description 16
229910001415 sodium ion Inorganic materials 0.000 claims abstract description 16
229910052700 potassium Inorganic materials 0.000 claims abstract description 15
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims abstract description 10
229910001424 calcium ion Inorganic materials 0.000 claims abstract description 9
159000000003 magnesium salts Chemical class 0.000 claims abstract description 9
229940029407 ioxaglate Drugs 0.000 claims abstract description 7
TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 claims abstract description 7
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 6
159000000007 calcium salts Chemical class 0.000 claims abstract description 6
AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims abstract description 5
229960004537 ioversol Drugs 0.000 claims abstract description 5
229960004647 iopamidol Drugs 0.000 claims abstract description 4
XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims abstract description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 35
229910052791 calcium Inorganic materials 0.000 claims description 32
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
229910052749 magnesium Inorganic materials 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
-1 iotrolane Chemical compound 0.000 claims description 5
239000008365 aqueous carrier Substances 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
150000003388 sodium compounds Chemical class 0.000 claims description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 8
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 abstract description 3
XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 abstract description 2
229960003182 iotrolan Drugs 0.000 abstract description 2
230000000694 effects Effects 0.000 description 32
239000000203 mixture Substances 0.000 description 32
150000001768 cations Chemical class 0.000 description 27
238000007792 addition Methods 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
208000003663 ventricular fibrillation Diseases 0.000 description 12
150000002500 ions Chemical class 0.000 description 11
230000002776 aggregation Effects 0.000 description 9
238000004220 aggregation Methods 0.000 description 9
206010003119 arrhythmia Diseases 0.000 description 9
230000006793 arrhythmia Effects 0.000 description 9
210000003743 erythrocyte Anatomy 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
229910001868 water Inorganic materials 0.000 description 9
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 8
239000012895 dilution Substances 0.000 description 8
238000010790 dilution Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
239000008215 water for injection Substances 0.000 description 8
150000001805 chlorine compounds Chemical class 0.000 description 7
210000002216 heart Anatomy 0.000 description 7
229910052740 iodine Inorganic materials 0.000 description 7
239000011630 iodine Substances 0.000 description 7
229910052751 metal Inorganic materials 0.000 description 7
239000002184 metal Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000001988 toxicity Effects 0.000 description 7
231100000419 toxicity Toxicity 0.000 description 7
206010020852 Hypertonia Diseases 0.000 description 6
230000000747 cardiac effect Effects 0.000 description 6
230000010247 heart contraction Effects 0.000 description 6
229910001425 magnesium ion Inorganic materials 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
239000001103 potassium chloride Substances 0.000 description 6
235000011164 potassium chloride Nutrition 0.000 description 6
238000011835 investigation Methods 0.000 description 5
239000002611 ionic contrast media Substances 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 4
238000002583 angiography Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
238000011160 research Methods 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
206010047284 Ventricular asystole Diseases 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
210000000663 muscle cell Anatomy 0.000 description 3
239000003690 nonionic contrast media Substances 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
229910001414 potassium ion Inorganic materials 0.000 description 3
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
230000003293 cardioprotective effect Effects 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000002586 coronary angiography Methods 0.000 description 2
229960005423 diatrizoate Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000004217 heart function Effects 0.000 description 2
229960000824 iopentol Drugs 0.000 description 2
IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 2
229960002603 iopromide Drugs 0.000 description 2
DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
229960003194 meglumine Drugs 0.000 description 2
229960000554 metrizamide Drugs 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
KZYHGCLDUQBASN-UHFFFAOYSA-N 1-n,1-n,3-n,3-n,5-n,5-n-hexakis(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3,5-tricarboxamide Chemical compound OCCN(CCO)C(=O)C1=C(I)C(C(=O)N(CCO)CCO)=C(I)C(C(=O)N(CCO)CCO)=C1I KZYHGCLDUQBASN-UHFFFAOYSA-N 0.000 description 1
DFDJVFYYDGMDTB-BIYVAJLZSA-N 1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[[(3s,4r,5s)-3,4,5,6-tetrahydroxy-2-oxohexanoyl]amino]benzene-1,3-dicarboxamide Chemical compound OCC(O)CNC(=O)C1=C(I)C(NC(=O)C(=O)[C@@H](O)[C@H](O)[C@@H](O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I DFDJVFYYDGMDTB-BIYVAJLZSA-N 0.000 description 1
IWLIBARWYNRYQO-OCPVLIPCSA-N 3,5-diacetamido-2,4,6-triiodo-n-methyl-n-[2-[methyl-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]amino]-2-oxoethyl]benzamide Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CN(C)C(=O)CN(C)C(=O)C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I IWLIBARWYNRYQO-OCPVLIPCSA-N 0.000 description 1
HUHDYASLFWQVOL-WZTVWXICSA-N 3-[[2-[[3-[acetyl(methyl)amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I HUHDYASLFWQVOL-WZTVWXICSA-N 0.000 description 1
MKMHLTWTZQIVCH-SFNQMWQSSA-N 3-[acetyl(2-hydroxyethyl)amino]-2,4,6-triiodo-n-methyl-5-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]benzamide Chemical compound CNC(=O)C1=C(I)C(NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(I)C(N(CCO)C(C)=O)=C1I MKMHLTWTZQIVCH-SFNQMWQSSA-N 0.000 description 1
ODYPLCHSCOJEIZ-GMYJMXFCSA-N 3-[acetyl(methyl)amino]-n-(2-hydroxyethyl)-2,4,6-triiodo-5-[[(2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl]amino]benzamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=C(I)C(C(=O)NCCO)=C1I ODYPLCHSCOJEIZ-GMYJMXFCSA-N 0.000 description 1
OQHLOKBHRXMXLD-UHFFFAOYSA-N 5-[3-[3-[3,5-bis[2,3-dihydroxypropyl(methyl)carbamoyl]-2,4,6-triiodoanilino]-3-oxopropyl]sulfanylpropanoylamino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1-n,3-n-dimethylbenzene-1,3-dicarboxamide Chemical compound OCC(O)CN(C)C(=O)C1=C(I)C(C(=O)N(CC(O)CO)C)=C(I)C(NC(=O)CCSCCC(=O)NC=2C(=C(C(=O)N(C)CC(O)CO)C(I)=C(C(=O)N(C)CC(O)CO)C=2I)I)=C1I OQHLOKBHRXMXLD-UHFFFAOYSA-N 0.000 description 1
RHISTIGVAKTTCM-UHFFFAOYSA-N 5-[[3-[3,5-bis(1,3-dihydroxypropan-2-ylcarbamoyl)-n-(2-hydroxyethyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2-hydroxyethyl)amino]-1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C(I)C=1N(CCO)C(=O)CC(=O)N(CCO)C1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I RHISTIGVAKTTCM-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000022900 cardiac muscle contraction Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
231100000045 chemical toxicity Toxicity 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960004901 iodamide Drugs 0.000 description 1
VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 description 1
229950002407 iodecimol Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229950008828 ioglucol Drugs 0.000 description 1
229950006335 ioglunide Drugs 0.000 description 1
229960000780 iomeprol Drugs 0.000 description 1
NJKDOADNQSYQEV-UHFFFAOYSA-N iomeprol Chemical compound OCC(=O)N(C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NJKDOADNQSYQEV-UHFFFAOYSA-N 0.000 description 1
229950007842 iosarcol Drugs 0.000 description 1
229950011065 iosimide Drugs 0.000 description 1
229950011097 iotasul Drugs 0.000 description 1
229940029378 iothalamate Drugs 0.000 description 1
229960002611 ioxilan Drugs 0.000 description 1
UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960004712 metrizoic acid Drugs 0.000 description 1
GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940037001 sodium edetate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0452—Solutions, e.g. for injection

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Liquid Crystal (AREA)
Medicinal Preparation (AREA)
Devices For Indicating Variable Information By Combining Individual Elements (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Lubricants (AREA)
Silicates, Zeolites, And Molecular Sieves (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Paints Or Removers (AREA)
Treatments Of Macromolecular Shaped Articles (AREA)
Compositions Of Macromolecular Compounds (AREA)

NO923485A 1990-03-09 1992-09-08 Kontrastmedier NO304352B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP90200580A EP0390242B1 (en)	1989-03-17	1990-03-09	Contrast media
GB909020091A GB9020091D0 (en)	1990-09-14	1990-09-14	Contrast media
PCT/EP1991/000425 WO1991013636A1 (en)	1990-03-09	1991-03-07	Contrast media

Publications (3)

Publication Number	Publication Date
NO923485D0 NO923485D0 (no)	1992-09-08
NO923485L NO923485L (no)	1992-11-05
NO304352B1 true NO304352B1 (no)	1998-12-07

Family

ID=10682193

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923485A NO304352B1 (no)	1990-03-09	1992-09-08	Kontrastmedier

Country Status (32)

Country	Link
US (2)	US5328680A (sh)
EP (1)	EP0521880B2 (sh)
JP (1)	JP3215703B2 (sh)
KR (1)	KR100189271B1 (sh)
CN (1)	CN1055864C (sh)
AT (1)	ATE141519T1 (sh)
CA (1)	CA2076861A1 (sh)
CZ (1)	CZ285071B6 (sh)
DE (1)	DE69121562T3 (sh)
DK (1)	DK0521880T4 (sh)
DZ (1)	DZ1506A1 (sh)
EG (1)	EG19889A (sh)
ES (1)	ES2090315T5 (sh)
FI (1)	FI100698B (sh)
GB (1)	GB9020091D0 (sh)
GE (1)	GEP19971155B (sh)
GR (2)	GR3020842T3 (sh)
HK (1)	HK1003563A1 (sh)
HR (1)	HRP930773B1 (sh)
HU (1)	HU217075B (sh)
IE (1)	IE76916B1 (sh)
IL (1)	IL97455A (sh)
LV (1)	LV10058B (sh)
MY (1)	MY105493A (sh)
NO (1)	NO304352B1 (sh)
OA (1)	OA09667A (sh)
PT (1)	PT96978B (sh)
RO (1)	RO111543B1 (sh)
SK (1)	SK278621B6 (sh)
TR (1)	TR25738A (sh)
WO (1)	WO1991013636A1 (sh)
YU (1)	YU48683B (sh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1256248B (it) *	1992-12-24	1995-11-29	Bracco Spa	Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
GB9419203D0 (en) *	1994-09-23	1994-11-09	Nycomed Innovation Ab	Contrast media
GB9419206D0 (en) *	1994-09-23	1994-11-09	Nycomed Innovation Ab	Contrast media
WO1997026862A2 (de) *	1996-01-25	1997-07-31	Schering Aktiengesellschaft	Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung
DE19648650C2 (de) *	1996-01-29	1998-07-02	Schering Ag	Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
DE10126405A1 (de) *	2001-05-22	2003-02-27	Trommsdorff Gmbh & Co	Physiologisch verträgliche Kalium- und Magnesiumsalze enthaltendes pharmazeutisches Präparat sowie dessen Verwendung zur Prophylaxe und/oder Therapie von QT-Zeitverlängerungen
US7498018B2 (en) *	2003-10-03	2009-03-03	Bracco Diagnostics Inc.	Contrast media for use in medical and diagnostic procedures and methods of using the same
DE102005028882A1 (de) *	2005-06-22	2007-01-04	Siemens Ag	Lösung und Verfahren zum Unterstützen der Bildgebung an einem Patienten
JP5290773B2 (ja)	2006-02-15	2013-09-18	ジーイー・ヘルスケア・アクスイェ・セルスカプ	造影剤
EP1998813A2 (en) *	2006-03-29	2008-12-10	GE Healthcare AS	Method to produce hyperpolarised carboxylates and sulphonates in the presence of inorganic cations
FR2899581B1 (fr) *	2006-04-07	2008-06-27	Guerbet Sa	Procede d'atomisation du ioxilan
US7662859B2 (en)	2007-02-16	2010-02-16	Ge Healthcare As	Contrast agents
CN103980154B (zh)	2007-07-12	2015-02-25	通用电气医疗集团股份有限公司	造影剂
CN101821231A (zh)	2007-10-12	2010-09-01	通用电气医疗集团股份有限公司	对比剂
CN101820923A (zh)	2007-10-12	2010-09-01	通用电气医疗集团股份有限公司	对比剂
JP2011500532A (ja)	2007-10-12	2011-01-06	ジーイー・ヘルスケア・アクスイェ・セルスカプ	造影剤
WO2009047315A1 (en)	2007-10-12	2009-04-16	Ge Healthcare As	Contrast agents
US20110256068A1 (en)	2009-01-09	2011-10-20	Wistand Lars-Goeran	Contrast media compositions
EP2243767A1 (en)	2009-04-21	2010-10-27	Bracco Imaging S.p.A	Process for the iodination of aromatic compounds
US8815210B2 (en)	2009-10-29	2014-08-26	Ge Healthcare As	Diagnostic composition comprising plasma cations having superior safety profile
CN102114249B (zh) *	2009-12-30	2013-01-30	四川大学华西医院	一种携氧冠脉造影剂及其制备方法
US20140065076A1 (en) *	2012-08-30	2014-03-06	Otsuka Pharmaceutical Co. Ltd.	Container with concentrated substance and method of using the same
BR112015024564A2 (pt)	2013-03-27	2017-07-18	Ge Healthcare As	solução de excipiente aquosa, conjunto, e, métodos para diluição de uma composição diagnóstica, para produzir uma solução de excipiente aquosa, e de diagnóstico e detecção de imagem
RU2683568C1 (ru) *	2013-12-04	2019-03-29	Ховионе Сайентиа Лимитед	Композиции, корригирующие вкус контрастных средств

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1858142A (en) *	1928-01-21	1932-05-10	Nat Aniline & Chem Co Inc	Colloidal mono-sodium tetraiodophenolphthalein
NL127881C (sh) *	1963-03-25
US3175952A (en) *	1963-05-29	1965-03-30	Sterling Drug Inc	Aqueous radiopaque solutions containing sodium and calcium ions
GB1069437A (en) *	1963-10-23	1967-05-17	Nyegaard & Co As	Injectable x-ray contrast media
DE2909439A1 (de) *	1979-03-08	1980-09-18	Schering Ag	Neue nichtionische roentgenkontrastmittel
DE2928417A1 (de) *	1979-07-12	1981-01-29	Schering Ag	Trijodierte basen
DE3038853A1 (de) *	1980-10-10	1982-05-27	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue n-hydroxy-alkylierte dicarbonsaeure-bis-(3,5-dicarbamoyl-2,4,6-trijodanilide), deren herstellung und diese enthaltende roentgenkonstrastmittel (ii)
US4957939A (en) *	1981-07-24	1990-09-18	Schering Aktiengesellschaft	Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
EP0185759B2 (en) *	1984-06-22	2004-06-02	Btg International Limited	Electrolyte solutions and (in vivo) use thereof
ATE72398T1 (de) *	1984-06-22	1992-02-15	Richard L Veech	Polyanionische materialien enthaltende elektrolytloesungen.
US4863714A (en) *	1987-02-05	1989-09-05	Cook Imaging Corporation	Sterilization of compositions of limited stability
JPH0625094B2 (ja) *	1988-03-01	1994-04-06	マリンクロット，インコーポレイテッド	非イオン性ｘ線コントラスト剤、組成物及び方法
US5011925A (en) *	1989-03-09	1991-04-30	Mallinckrodt, Inc.	Morpholinoamido EDTA derivatives
GB8906130D0 (en) *	1989-03-17	1989-05-04	Nycomed As	Compositions

1990
- 1990-09-14 GB GB909020091A patent/GB9020091D0/en active Pending
1991
- 1991-03-06 IL IL9745591A patent/IL97455A/en not_active IP Right Cessation
- 1991-03-06 DZ DZ910035A patent/DZ1506A1/fr active
- 1991-03-07 CA CA002076861A patent/CA2076861A1/en not_active Abandoned
- 1991-03-07 DK DK91905048T patent/DK0521880T4/da active
- 1991-03-07 HU HU9202870A patent/HU217075B/hu unknown
- 1991-03-07 YU YU40891A patent/YU48683B/sh unknown
- 1991-03-07 RO RO92-01165A patent/RO111543B1/ro unknown
- 1991-03-07 EP EP91905048A patent/EP0521880B2/en not_active Expired - Lifetime
- 1991-03-07 DE DE69121562T patent/DE69121562T3/de not_active Expired - Lifetime
- 1991-03-07 AT AT91905048T patent/ATE141519T1/de not_active IP Right Cessation
- 1991-03-07 WO PCT/EP1991/000425 patent/WO1991013636A1/en active IP Right Grant
- 1991-03-07 US US07/923,926 patent/US5328680A/en not_active Ceased
- 1991-03-07 ES ES91905048T patent/ES2090315T5/es not_active Expired - Lifetime
- 1991-03-07 JP JP50518691A patent/JP3215703B2/ja not_active Expired - Lifetime
- 1991-03-08 PT PT96978A patent/PT96978B/pt not_active IP Right Cessation
- 1991-03-08 SK SK619-91A patent/SK278621B6/sk not_active IP Right Cessation
- 1991-03-08 IE IE77591A patent/IE76916B1/en not_active IP Right Cessation
- 1991-03-08 CZ CS91619A patent/CZ285071B6/cs not_active IP Right Cessation
- 1991-03-09 MY MYPI91000386A patent/MY105493A/en unknown
- 1991-03-09 CN CN91101421A patent/CN1055864C/zh not_active Expired - Lifetime
- 1991-03-09 EG EG13791A patent/EG19889A/xx active
- 1991-03-11 TR TR91/0237A patent/TR25738A/xx unknown
1992
- 1992-08-24 OA OA60263A patent/OA09667A/en unknown
- 1992-09-04 FI FI923962A patent/FI100698B/fi active
- 1992-09-08 NO NO923485A patent/NO304352B1/no not_active IP Right Cessation
- 1992-09-09 KR KR1019920702186A patent/KR100189271B1/ko not_active Ceased
- 1992-12-30 LV LVP-92-595A patent/LV10058B/lv unknown
1993
- 1993-04-02 HR HR930773A patent/HRP930773B1/xx not_active IP Right Cessation
- 1993-07-26 GE GEAP19931164A patent/GEP19971155B/en unknown
1996
- 1996-03-15 US US08/616,245 patent/USRE36418E/en not_active Expired - Lifetime
- 1996-08-22 GR GR960402066T patent/GR3020842T3/el unknown
1998
- 1998-03-27 HK HK98102624A patent/HK1003563A1/xx not_active IP Right Cessation
2000
- 2000-07-05 GR GR20000401583T patent/GR3033898T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2090315T3 (es)	1996-10-16
CN1056058A (zh)	1991-11-13
NO923485L (no)	1992-11-05
ES2090315T5 (es)	2000-08-01
AU645544B2 (en)	1994-01-20
DZ1506A1 (fr)	2004-09-13
IL97455A0 (en)	1992-06-21
YU48683B (sh)	1999-06-15
DE69121562D1 (de)	1996-09-26
GEP19971155B (en)	1997-08-11
CS9100619A2 (en)	1991-09-15
TR25738A (tr)	1993-09-01
DK0521880T3 (da)	1996-09-09
EP0521880B2 (en)	2000-05-31
HU9202870D0 (en)	1992-11-30
USRE36418E (en)	1999-11-30
GB9020091D0 (en)	1990-10-24
HU217075B (hu)	1999-11-29
IE76916B1 (en)	1997-11-05
KR100189271B1 (ko)	1999-06-01
SK278621B6 (en)	1997-11-05
JP3215703B2 (ja)	2001-10-09
IL97455A (en)	1995-11-27
US5328680A (en)	1994-07-12
EP0521880B1 (en)	1996-08-21
FI100698B (fi)	1998-02-13
DE69121562T3 (de)	2000-11-23
GR3033898T3 (en)	2000-11-30
FI923962A0 (fi)	1992-09-04
WO1991013636A1 (en)	1991-09-19
AU7345191A (en)	1991-10-10
DK0521880T4 (da)	2000-09-04
EG19889A (en)	1996-03-31
EP0521880A1 (en)	1993-01-13
HUT62490A (en)	1993-05-28
OA09667A (en)	1993-05-15
PT96978B (pt)	2001-07-31
ATE141519T1 (de)	1996-09-15
RO111543B1 (ro)	1996-11-29
PT96978A (pt)	1991-10-31
HRP930773B1 (en)	2000-10-31
CA2076861A1 (en)	1991-09-10
FI923962L (fi)	1992-09-04
DE69121562T2 (de)	1997-01-16
LV10058B (en)	1994-10-20
GR3020842T3 (en)	1996-11-30
JPH05504953A (ja)	1993-07-29
LV10058A (lv)	1994-05-10
IE910775A1 (en)	1991-09-11
CZ285071B6 (cs)	1999-05-12
HK1003563A1 (en)	1998-10-30
HRP930773A2 (en)	1997-10-31
NO923485D0 (no)	1992-09-08
YU40891A (sh)	1994-04-05
CN1055864C (zh)	2000-08-30
MY105493A (en)	1994-10-31

Publication	Publication Date	Title
NO304352B1 (no)	1998-12-07	Kontrastmedier
KR20140109420A (ko)	2014-09-15	저농도의 요오드를 포함하는 ｘ선 영상화 조영 매질 및 ｘ선 영상화 방법
JP3049366B2 (ja)	2000-06-05	造影剤
RU2088261C1 (ru)	1997-08-27	Контрастное средство для ангиографии коронарных сосудов и способ его получения
RU2098131C1 (ru)	1997-12-10	Контрастная среда и способ ее получения
AU645544C (en)	1998-08-20	Contrast media

Legal Events

Date	Code	Title	Description
2011-04-18	MK1K	Patent expired